Market Cap (In PLN)
586.01 Million
Revenue (In PLN)
-
Net Income (In PLN)
-13.68 Million
Avg. Volume
8323.00
- Currency
- PLN
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 58.9-98.0
- PE
- -31.48
- EPS
- -3.78
- Beta Value
- 1.582
- ISIN
- PLBCLTX00019
- CUSIP
- -
- CIK
- -
- Shares
- 4924468.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Lukasz Bzdzion
- Employee Count
- -
- Website
- https://bioceltix.com
- Ipo Date
- 2021-11-08
- Details
- Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
More Stocks
-
NINTFNinety One Group
NINTF
-
SGR-UNSlate Grocery REIT
SGR-UN
-
CCOI
-
MLTX
-
DHPINDDHP India Limited
DHPIND
-
1257
-
IGC
-
8101